Characteristics, Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients with Multifocal Motor...

Area of Science:

• Neurology
• Rare Diseases
• Health Economics

Background:

• Multifocal motor neuropathy (MMN) is a rare, progressive nerve disorder causing limb weakness without sensory loss.
• MMN is frequently misdiagnosed as other conditions, such as amyotrophic lateral sclerosis (ALS), complicating diagnosis and treatment.
• Accurate diagnosis and understanding the economic impact of MMN are critical for patient management.

Purpose of the Study:

• To assess patient characteristics, treatment patterns, and the economic burden of MMN in the United States.
• To differentiate between MMN and MMN-mimic conditions using claims data.
• To evaluate healthcare utilization and costs associated with MMN and MMN-mimic conditions.

Main Methods:

• Retrospective analysis of the Optum Research Database (2016-2020) using diagnostic and nondiagnostic medical claims.
• Patients were categorized into MMN or MMN-mimic cohorts based on specific diagnostic criteria and follow-up for ALS.
• Outcomes measured included treatment patterns (especially IVIG use), differential diagnoses, healthcare utilization, and associated costs.

Main Results:

• Of 904 patients, 37% had MMN and 63% had MMN-mimic conditions; MMN patients were younger on average.
• MMN patients showed higher utilization of MMN-related medications, particularly IVIG, and incurred significantly higher total and MMN-related healthcare costs.
• Over 70% of patients had at least one differential diagnosis, and many MMN patients did not receive IVIG, indicating potential undertreatment or diagnostic code misattribution.

Conclusions:

• A significant proportion of patients initially diagnosed with MMN were later identified with other disorders, highlighting diagnostic challenges.
• Patients with confirmed MMN experience a greater economic burden compared to those with MMN-mimic conditions.
• Increased education on accurate MMN diagnosis is essential to ensure patients receive timely and guideline-recommended treatments, such as IVIG.